Neogenomics
Company leaders said that practical steps are being taken to recover from earlier underperformance and support planned growth in NGS and residual disease testing.
New Data Suggests Liquid Biopsy Provides Early ID of Breast Cancer Patients Destined to Recur
Premium
Investigators shared results of a study this week in which ctDNA residual disease testing gave advance notice of late recurrences in surgically resected HR+ HER2- patients.
The firm is sketching plans to drive greater revenue growth by improving its laboratory processes and developing broader NGS panels.
NeoGenomics, Eli Lilly to Offer Molecular Testing to Non-Small Cell Lung Cancer Patients
Patients will have the opportunity to be tested with NeoGenomics' next-generation sequencing-based NeoType DNA and RNA Assay at no cost.
360Dx Top 30 Falls Slightly in March
Of the 30 companies in the index, 17 saw declines in their stock prices, while 13 saw share price increases.
Feb 17, 2022
Nov 4, 2021
Nov 4, 2021
NeoGenomics Q3 Revenues Drop 3 Percent
Aug 6, 2021
NeoGenomics Q2 Revenues Grow 40 Percent
May 7, 2021
Mar 24, 2021